Central, peripheral and hemodynamic effects of nanoformulated anandamide during hypertension.

FERES MOCAYAR; LUCÍA FUENTES; WALTER MANUCHA; GARCÍA SEBASTIÁN; DIEGO KASSUHA; VIRNA MARTÍN GIMENÉZ; MANUEL GUEVARA; ROBERTO YUNES

San Luis

Congreso; XXXVII Reunión científica anual de la sociedad de biología de cuyo; 2019

Sociedad de Biología de Cuyo

Hypertensive lesions - dependent on inflammatory processes - would cause alterations at the central nervous system level with peripheral and hemodynamic consequences. Anandamide (AEA), an endocannabinoid, protects neurons from inflammatory damage. However, the administration of free AEA may produce central side effects but its controlled release by nanoformulations would reduce or eliminate them. We evaluated possible effects of nanoformulated AEA on blood pressure, central and systemic inflammatory markers and behavioral alterations in SHR and WKY. We used male rats of 250-300 g (N = 7 per group) normotensive (WKY) and hypertensive (SHR) with and without treatment with nanoformulated AEA at a weekly dose of 5 mg/kg IP, for four weeks. We determined systolic blood pressure, expression of WT-1, Hsp-70, AT1 and iNOS in brain tissue, behavior, and blood levels of ultrasensitive PCR, IL-1, IL-6, TNF-alpha, Hsp-70, NADPH oxidase and nitrites. We use ANOVA II and the Bonferroni post-test (p